Achillion Pharmaceuticals



Odalasvir (also known as ACH-3102) is a structurally-distinct, second-generation NS5A inhibitor, which achieved 100 percent SVR12 in a phase 2 study of genotype 1 HCV patients treated for six weeks with ACH-3102 + sofosbuvir. In multiple phase 2 studies, ACH-3102 has demonstrated a high barrier to the emergence of resistance.